Market intelligence for the peptide supply chain
APIs ·

Canada seizes more than 11,400 vials in peptide import crackdown

November 6, 2026 · TideMetrix Brief
TideMetrix TakeCanada's crackdown on unauthorized peptide imports highlights the risks of unverified supply chains, with bacterial contamination findings reinforcing the importance of supplier traceability and pharmaceutical-grade quality controls.

Health Canada has seized more than 11,400 vials of unauthorized injectable products linked to Shanghai ERP Peptide Biotechnology and two Canadian online retailers, following findings of bacterial contamination in tested products.

In a November 6 advisory, the regulator identified truenorthbiolabs.ca and bcaxiompeptide.com as retailers selling ERP products. Both websites are no longer active following enforcement action, which included court-authorized searches and seizures.

Testing of ERP products detected bacteria including Acinetobacter species and Cutibacterium acnes. The regulator did not specify how many of the seized vials were contaminated.

Products identified in the investigation included tirzepatide, retatrutide, tesamorelin and MOTS-C, alongside non-peptide drugs.

Health Canada said it had instructed ERP to stop selling unauthorized peptides into Canada and was working with the Canada Border Services Agency to intercept shipments entering the country.

The enforcement action concerns unauthorized retail injectable products rather than qualified pharmaceutical API supply chains. It does not establish contamination among regulated peptide API manufacturers or indicate a broader restriction on legitimate industrial imports.

For peptide manufacturers and buyers, the case underscores the importance of verifying supplier identity, manufacturing provenance and product documentation rather than relying solely on advertised purity or testing claims.

Sources

← Back to News